Fecesni galektin-1 – potencijalni marker kolorektalnog karcinoma i težine bolesti

  • Milan Jovanovic Military Medical Academy, Clinic for General Surgery, Belgrade, Serbia
  • Nevena Gajovic University of Kragujevac, Faculty of Medical Sciences, Center for Molecular Medicine and Stem Cell Research, Kragujevac, Serbia
  • Natasa Zdravkovic University of Kragujevac, Faculty of Medical Sciences, Department of Internal Medicine, Kragujevac, Serbia
  • Marina Jovanovic University of Kragujevac, Faculty of Medical Sciences, Department of Internal Medicine, Kragujevac, Serbia
  • Milena Jurisevic University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, Kragujevac, Serbia
  • Danilo Vojvodic Military Medical Academy, Institute for Medical Research, Belgrade, Serbia; University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Darko Mirkovic Military Medical Academy, Clinic for General Surgery, Belgrade, Serbia; University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Bosko Milev Military Medical Academy, Belgrade, Serbia; University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
  • Veljko Maric University of East Sarajevo, Faculty of Medicine, Department of Surgery, Foča, Bosnia and Herzegovina
  • Nebojsa Arsenijevic University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP171201007J
Ključne reči: kolorektalne neoplazme, karcinom, stolica, galektin-1, bolest, progresija

Sažetak


Apstrakt

 

Uvod/Cilj. Kolorektalni karcinom (colorecral carcinoma - CRC) je jedan od najučestalijih karcinoma na svetu. CRC se često dijagnostikuje u uznapredovalim stadijumima sa lošom prognozom, ukazujući na potrebu za novim dijagnostičkim i prognostičkim markerima. Cilj ove studije bio je utvrđivanje sistemskih i fekalnih vrednosti galektina-1 (gal-1) i odnosa između gal-1 i proinflamacijskih citokina: faktoru nekroze tumora alfa (TNF-α), interleukina-1 beta (IL-1β) i interferona-gama (IFN-γ) kod bolesnika sa CRC i odnosa sa kli­ničko-patološkim aspektima bolesti. Metode. Analizirani su uzorci krvi i tečne frakcije fecesa 58 bolesnika sa CRC. Serumski i fekalni nivoi TNF-α, IL-1β, IFN-γ i gal-1 su mereni korišćenjem senzitivnog enzyme-linked immunosorbent assay (ELISA) testa. Rezultati. Fekalni nivo gal-1 povećan je kod bolesnika sa CRC sa velikim nuklearnim gradusom i slabo diferentovanim tumorskim tkivom. Odnos gal-1/TNF-α u serumu i fecesu značajno je veći kod bolesnika sa uznapredovalim tumor-nodus-metastaza (TNM) stadijumom, kao i detektabilnom invazijom limfnih i krvnih sudova. Odnosi gal-1/TNF-α i gal-1/IFN-γ su povećani u serumima bolesnika sa metastazama u plućima/jetri ili peritonealnom karcinomatozom, dok je povećan odnos gal-1/IL-1 detektovan samo u serumu bolesnika sa metastazama u plućima. Tako­đe, primećena je pozitivna korelacija između vrednosti gal-1 u fecesu i histološkog tipa tumora i biomarkera alfa-feto­proteina (AFP) i cancer antigen 19-9 (CA 19-9). Vrednosti gal-1 u fecesu veće od 13,708.29 pg/g predstavljaju visoko osetljiv i specifičan marker za histološku diferencijaciju tumorskog tkiva. Zaključak. Naši rezultati ukazuju na to da predominacija gal-1 nad proinflamacijskim citokinima, TNF-α, IL-1β, IFN-γ, kod bolesnika sa uznapredovalom i progresivnom bolešću ističe imunomodulatornu ulogu gal-1 u ograničavanju proinflamacijskih procesa. Vrednosti gal-1 u fecesu mogu se koristiti kao marker procene težine kolorektalnog karcinoma.

Reference

REFERENCES

Global Burden of Disease Cancer Collaboration. Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, et al. The Global Burden of Cancer 2013. JAMA Oncol 2015; 1(4): 505–27.

Zdravkovic N, Pavlovic M, Radosavljevic G, Jovanovic M, Arsenijevic A, Zdravkovic N, et al. Serum levels of immunosuppressive cy-tokines and tumor markers in metastatic colorectal carcinoma. JBUON 2017; 22(5): 1–8.

Zdravkovic ND, Jovanovic IP, Radosavljevic GD, Arsenijevic AN, Zdravkovic ND, Mitrovic SLJ, et al. Potential Dual Immunomo-dulatory Role of VEGF in Ulcerative Colitis and Colorectal Carcinoma. Int J Med Sci 2014; 11(9): 936–47

Wu KL, Chen HH, Pen CT, Yeh WL, Huang EY, Hsiao CC, et al. Circulating Galectin-1 and 90K/Mac-2BP Correlated with the Tumor Stages of Patients with Colorectal Cancer. Biomed Res Int 2015; 2015: 306964.

Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treat-ment outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008; 14(36): 5584–9; discussion 5588.

Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease Gastroen-terology 2000; 119(1): 15–22.

Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, et al. A simple method for assessing intestinal in-flammation in Crohn's disease. Gut 2000; 47(4): 506–13.

Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ, Do IG, et al. High galectin-1 expression correlates with poor prognosis and is in-volved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 2012; 48(12): 1914–21.

Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, et al. Galec-tin-1 overexpression promotes progression and chemoresis-tance to cisplatin in epithelial ovarian cancer. Cell Death Dis 2014; 5: e991.

Ouyang J, Plütschow A, Pogge von Strandmann E, Reiners KS, Ponad-er S, Rabinovich GA, et al. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood 2013; 121(17): 3431–3

Chen L, Yao Y, Sun L, Zhou J, Liu J, Wang J, et al. Clinical im-plication of the serum galectin-1 expression in epithelial ova-rian cancer patients. J Ovarian Res 2015; 8: 78.

Al-Salam S, Hashmi S. Galectin-1 in early acute myocardial in-farction. PLoS One 2014; 9(1): e86994.

Nakahara S, Raz A. Biological modulation by lectins and their ligands in tumor progression and metastasis. Anticancer Agents Med Chem 2008; 8(1): 22–36.

Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006; 16(11): 137R–57R.

Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, et al. Galectin-1 and its involvement in hepatocellular car-cinoma aggressiveness. Mol Med. 2010; 16(3–4): 102–15.

Almkvist J, Karlsson A. Galectins as inflammatory mediators. Glycoconj J 2004; 19(7–9): 575–81.

Heilmann RM, Cranford SM, Ambrus A, Grützner N, Schellenberg S, Ruaux CG, et al. Validation of an enzyme-linked immuno-sorbent assay (ELISA) for the measurement of canine S100A12. Vet Clin Pathol 2016; 45(1): 135–47.

Prakash N, Stumbles P, Mansfield C. Initial Validation of Cyto-kine Measurement by ELISA in Canine Feces. Open J Vet Med 2013; 3: 282–8.

Jovanovic M, Zdravkovic N, Jovanovic I, Radosavljevic G, Gajovic N, Zdravkovic N, et al. TGF-β as a marker of ulcerative colitis and disease severity. Ser J Exp Clin Res 2017; 1–1. DOI: 10.1515/SJECR-2017-0019.

Wu MH, Hong TM, Cheng HW, Pan SH, Liang YR, Hong HC, et al. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reor-ganized actin cytoskeletons. Mol Cancer Res 2009; 7(3): 311–8.

Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A 2006; 103(43): 15975–80.

Tang D, Gao J, Wang S, Yuan Z, Ye N, Chong Y, et al. Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer. Tumour Biol 2015; 36(7): 5617–26.

Grosset AA, Labrie M, Vladoiu MC, Yousef EM, Gaboury L, St-Pierre Y. Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget 2016; 7(14): 18183–203.

Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Rabinovich GA, Bieche I, et al. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. Eur J Cancer 2014; 50(14): 2463–77.

Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, et al. Ga-lectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007; 120(11): 2331–8.

Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumori-genesis in Kaposi’s sarcoma. J Exp Med 2012; 209(11): 1985–2000.

Brandt B, Abou-Eladab EF, Tiedge M and Walzel H. Role of the JNK/c-Jun/AP-1 signaling pathway in galectin-1-induced T-cell death. Cell Death Dis 2010; 1: e23

Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994; 76(4): 597–8.

D’Haene N, Sauvage S, Maris C, Adanja I, Le Mercier M, Decaes-tecker C, et al. VEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis. PLoS One 2013; 8(6): e67029.

Suzuki O, Abe M. Galectin-1-mediated cell adhesion, invasion and cell death in human anaplastic large cell lymphoma: regulatory roles of cell surface glycans. Int J Oncol 2014; 44(5): 1433–42.

Johne B, Kronborg O, Tøn HI, Kristinsson J, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001; 36(3): 291–6.

Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N, et al. Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. Schizophr Res 2013; 147(1): 103–9.

Blaser C, Kaufmann M, Muller C, Zimmermann C, Wells V, Mallucci L, et al. Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced prolif eration of T cells. Eur J Immunol 1998; 28(8): 2311–9.

He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004; 279(6): 4705–12.

Allione A, Wells V, Forni G, Mallucci L, Novelli F. Betagalacto-side-binding protein (beta GBP) alters the cell cycle, upregu-lates expression of the alpha- and beta-chains of the IFN-gamma receptor, and triggers IFN-gamma-mediated apoptosis of activated human T lymphocytes. J Immunol 1998; 161(5): 2114–9.

Baum L.G, Blackall DP, Arias-Magallano S, Nanigian D, Uh SY, Browne JM, et al. Amelioration of graft versus host disease by galectin-1. Clin Immunol 2003; 109(3): 295–307.

Santucci L, Fiorucci S Rubinstein N, Mencarell, A, Palazzett, B, Federici B, et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 2003; 124(5): 1381–94.

van der Leij J, van den Berg A, Blokzijl T, Harms G, van Goor H, Zwiers P, et al. Dimeric galectin-1 induces IL-10 production in T-lymphocytes: an important tool in the regulation of the im-mune response. J Pathol 2004; 204(5): 511–8.

van den Brule, FA, Waltregny, D, and Castronovo, V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001; 193(1): 80–7.

Objavljeno
2021/05/11
Broj časopisa
Vol. 76 Br. 10 (2019): Vojnosanit Pregl
Rubrika
Originalni članak